LSUHSC Minority Based Community Clinical Oncology

{\fnSimHei\bord1\shad1\pos（200，288）} {\*\generator Msftedit 5.41.15.1515;}\viewkind4\uc1\pard\f0\fs16路易斯安那州立大学健康科学中心少数族裔社区临床肿瘤学项目（LSUHSC\par MBCCOP）仍然是东南部少数民族人群获得和参与临床试验的极好工具。 方面应受中华路易斯安那州的几种常见恶性肿瘤的发病率在统计学上显著增加， 美国其他地区（监测、流行病学和最终结果[SEER]估计）。重要的是， 大约70%的病人在国家医疗系统最大的城市医院（医疗中心的\par 路易斯安那州在新奥尔良[MCLNO]）是非洲裔美国人。不幸的是，非洲裔美国人传统上仍然是 在获得和参与肿瘤学临床试验方面代表性不足。这种试验有助于提供切割\标准 边缘疗法和预防策略。此外，临床上少数民族的子集评估 临床试验也可能提供关于在某些特定的疾病中潜在的药物基因组学差异的临床结果的重要信息。 非裔美国人对白人。然而，LSUHSC MBCCOP寻求减少试验参与方面的差距， 非裔美国人和白种人之间的差异重要的是，MBCCOP为社区提供的临床试验 包括治疗和预防目标。LSUHSC MBCCOP的目标包括： 通过针对多层次患者的干预措施，少数群体获得和参与治疗性临床试验 在乎2)通过针对\par的干预措施，增加少数群体获得和参与癌症预防临床试验的机会 多层次的病人护理。3)为了评估患者进入和参与临床试验的障碍， 城市学术医院系统总之，LSUHSC MBCCOP寻求增加参与审判的\par 通过教育和投资，少数民族人口开始评估这些障碍。fs20\par \参数 }

{\rtf1\ansi\ansicpg1252\deff0\deflang1033{\fonttbl{\f0\fswiss\fcharset0 Arial;}} {\*\generator Msftedit 5.41.15.1515;}\viewkind4\uc1\pard\f0\fs16 The Louisiana State University Health Sciences Center Minority Based Community Clinical Oncology Program (LSUHSC\par MBCCOP) remains an excellent vehicle for clinical trials access and participation in the minority population of Southeast\par Louisiana. Louisiana has a statistically significantly increased incidence of several common malignancies over the\par remainder of the United States (Surveillance, Epidemiology and End Results [SEER] estimate). Importantly,\par approximately 70% of patients seen in the largest urban hospital of the state medical system (The Medical Center of\par Louisiana at New Orleans [MCLNO]) are African American. Unfortunately, African Americans have traditionally remained\par underrepresented in terms of access to and participation in oncology clinical trials. Such trials serve to provide cutting\par edge therapies and prevention strategies to the local community. Additionally, subset evaluations of minorities on clinical\par trials may also provide important information on the clinical outcomes of potential pharmacogenomic differences in\par African Americans versus Caucasians. However, the LSUHSC MBCCOP seeks to decrease the gap in trials participation\par between African Americans and Caucasians. Importantly, the clinical trials that the MBCCOP provides for the community\par encompass both therapeutic and prevention objectives. The aims of the LSUHSC MBCCOP include 1) To increase\par minority access to and participation in therapeutic clinical trials through interventions targeting multiple levels of patient\par care. 2) To increase minority access to and participation in cancer prevention clinical trials through interventions targeting\par multiple levels of patient care. 3) To evaluate barriers to access and participation in clinical trials by patients in a large,\par urban, academic hospital system. In summary, the LSUHSC MBCCOP seeks to increase trials participation of the\par minority population through education and investi_lator initiated evaluation of barriers to these _loals.\fs20\par \par }